X-linked agammaglobulinemia (XLA)


X-linked agammaglobulinemia (XLA; also known as Bruton’s agammaglobulinemia) is the name for a condition that affects the body's abliity to make antibodies and fight infections. It belongs to a group of conditions known as antibody deficiencies. XLA affects only boys and its features include repeated episodes of bacterial infections affecting the ears, sinuses, nose, eyes, skin and the gastrointestinal tract (gut). It is a rare condition with about 510 people in a million affected.

Antibodies are made by white blood cells called B-cells or sometimes referred to
as B-lymphocytes. In XLA there are genetic changes known as mutations in the
Bruton’s tyrosine kinase (BTK) gene. These mutations block the development of
normal, mature B-cells that would normally make antibodies. As a result, people
with XLA have very few mature B-cells and cannot make immunoglobulins; that
is, the antibodies that are needed to protect the body against infections.

The aim of treatment in XLA is to replace the missing or defective antibodies
with purified immunoglobulins from the blood of healthy donors in order to
reduce the frequency and severity of infections. Although not a cure for XLA,
immunoglobulin replacement therapy is often enough to keep patients healthy
so that those affected can lead full and relatively normal lives. Children with XLA
should take part in regular school activities, including exercise, and do not need
to be limited in what they can do. It is important for the school to be aware of
the diagnosis, however.

Antibiotics are often needed to treat breakthrough bacterial infections that will
occur from time to time. A few individuals may need to take antibiotics every day
to protect them from infection or to treat chronic sinusitis or chronic bronchitis.
Patients with bronchiectasis (widening and scarring of the bronchial airways)
may need help from a physiotherapist to help clear their airways.

This page was reviewed by the Medical Advisory Panel April 2013. Revised July 2015.